1. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid. 2007; 14:179–83.
Article
2. Holanda DG, Acharya VK, Dogan A, Racusen LC, Atta MG. Atypical presentation of atypical amyloid. Nephrol Dial Transplant. 2011; 26:373–6.
Article
3. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019; 15:45–59.
Article
4. Leung N, Drosou ME, Nasr SH. Dysproteinemias and glomerular disease. Clin J Am Soc Nephrol. 2018; 13:128–39.
Article
5. Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017; 281:337–47.
Article
6. Manabe S, Iwasaki C, Hatano M, et al. AL amyloidosis with nonamyloid forming monoclonal immunoglobulin deposition: a case mimicking AHL amyloidosis. BMC Nephrol. 2018; 19:337.
Article
7. Nasr SH, Said SM, Valeri AM, et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013; 83:463–70.
Article
8. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012; 7:231–9.
Article
9. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114:4957–9.
Article